Category Archives: BioEngineering

ORBIS RESEARCH has recently announced Global Bioreactors and Fermenters Market report with all the critical analysis on current state of industry, demand for product, environment for investment and existing competition. Global Bioreactors and Fermenters Market report is a focused study on various market affecting factors and comprehensive survey of industry covering major aspects like product types, various applications, top regions, growth analysis, market potential, challenges for investor, opportunity assessments, major drivers and key players (The major players covered in Bioreactors and Fermenters are: Sartorius AG (BBI), ZETA, Danaher (Pall), Thermo Fisher, Pierre Guerin (DCI-Biolafitte), Merck KGaA, Bioengineering AG, Praj Hipurity Systems, Eppendorf AG, Applikon Biotechnology, Infors HT, Solaris, etc. )

Description

The Bioreactors and Fermenters market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4168186

Global Bioreactors and Fermenters Market the Major Players Covered in Bioreactors and Fermenters are: The major players covered in Bioreactors and Fermenters are: Sartorius AG (BBI), ZETA, Danaher (Pall), Thermo Fisher, Pierre Guerin (DCI-Biolafitte), Merck KGaA, Bioengineering AG, Praj Hipurity Systems, Eppendorf AG, Applikon Biotechnology, Infors HT, Solaris, etc. Among other players domestic and global, Bioreactors and Fermenters market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Global Bioreactors and Fermenters Market segmentation

Bioreactors and Fermenters market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Bioreactors and Fermenters market has been segmented into Single-use Bioreactors, Multiple-use Bioreactors, etc.

By Application, Bioreactors and Fermenters has been segmented into CROs, Academic and Research Institutes, Others, etc.

Browse the complete report @ https://www.orbisresearch.com/reports/index/global-bioreactors-and-fermenters-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

Global Bioreactors and Fermenters Market Regions and Countries Level Analysis

Regional analysis is another highly comprehensive part of the research and analysis study of the global Bioreactors and Fermenters market presented in the report. This section sheds light on the sales growth of different regional and country-level Bioreactors and Fermenters markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Bioreactors and Fermenters market.

The report offers in-depth assessment of the growth and other aspects of the Bioreactors and Fermenters market in important countries (regions), including United States, Canada, Mexico, Germany, France, United Kingdom, Russia, Italy, China, Japan, Korea, India, Southeast Asia, Australia, Brazil and Saudi Arabia, etc. It also throws light on the progress of key regional Bioreactors and Fermenters markets such as North America, Europe, Asia-Pacific, South America and Middle East & Africa.

Bioreactors and Fermenters competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Bioreactors and Fermenters sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Bioreactors and Fermenters sales, revenue and market share for each player covered in this report.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4168186

Table of Contents

1 Bioreactors and Fermenters Market Overview1.1 Product Overview and Scope of Bioreactors and Fermenters1.2 Classification of Bioreactors and Fermenters by Type1.2.1 Global Bioreactors and Fermenters Revenue by Type: 2015 VS 2019 VS 20251.2.2 Global Bioreactors and Fermenters Revenue Market Share by Type in 20191.2.3 OTC Interest Rate Derivatives1.2.4 OTC Forex Derivatives1.2.5 Others1.3 Global Bioreactors and Fermenters Market by Application1.3.1 Overview: Global Bioreactors and Fermenters Revenue by Application: 2015 VS 2019 VS 20251.3.2 OTC Options1.3.3 Forward1.3.4 SWAP1.3.5 Others1.4 Global Bioreactors and Fermenters Market by Regions1.4.1 Global Bioreactors and Fermenters Market Size by Regions: 2015 VS 2019 VS 20251.4.2 Global Market Size of Bioreactors and Fermenters (2015-2025)1.4.3 North America (USA, Canada and Mexico) Bioreactors and Fermenters Status and Prospect (2015-2025)1.4.4 Europe (Germany, France, UK, Russia and Italy) Bioreactors and Fermenters Status and Prospect (2015-2025)1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Bioreactors and Fermenters Status and Prospect (2015-2025)1.4.6 South America (Brazil, Argentina, Colombia) Bioreactors and Fermenters Status and Prospect (2015-2025)1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Bioreactors and Fermenters Status and Prospect (2015-2025)

2 Company Profiles2.1 GF Securities2.1.1 GF Securities Details2.1.2 GF Securities Major Business and Total Revenue (Financial Highlights) Analysis2.1.3 GF Securities SWOT Analysis2.1.4 GF Securities Product and Services2.1.5 GF Securities Bioreactors and Fermenters Revenue, Gross Margin and Market Share (2018-2019)2.2 SHANXI Securities2.2.1 SHANXI Securities Details2.2.2 SHANXI Securities Major Business and Total Revenue (Financial Highlights) Analysis2.2.3 SHANXI Securities SWOT Analysis2.2.4 SHANXI Securities Product and Services2.2.5 SHANXI Securities Bioreactors and Fermenters Revenue, Gross Margin and Market Share (2018-2019)2.3 GUOTAI JUNAN Securities2.3.1 GUOTAI JUNAN Securities Details2.3.2 GUOTAI JUNAN Securities Major Business and Total Revenue (Financial Highlights) Analysis2.3.3 GUOTAI JUNAN Securities SWOT Analysis2.3.4 GUOTAI JUNAN Securities Product and Services2.3.5 GUOTAI JUNAN Securities Bioreactors and Fermenters Revenue, Gross Margin and Market Share (2018-2019)2.4 ZHONGTAI Securities2.4.1 ZHONGTAI Securities Details2.4.2 ZHONGTAI Securities Major Business and Total Revenue (Financial Highlights) Analysis2.4.3 ZHONGTAI Securities SWOT Analysis2.4.4 ZHONGTAI Securities Product and Services2.4.5 ZHONGTAI Securities Bioreactors and Fermenters Revenue, Gross Margin and Market Share (2018-2019)2.5 INDUSTRIAL Securities

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155Email ID: [emailprotected]

Read this article:
Global Bioreactors and Fermenters Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 - Jewish Life News

The "Global Omega-3 Market Analysis & Trends - Industry Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

The Global Omega-3 Market is poised to grow strong during the forecast period 2018 to 2028. Some of the prominent trends that the market is witnessing include rise in focus on preventive healthcare, growing application profiling and increase in demand for food fortification.

This industry report analyzes the market estimates and forecasts of all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2017, 2018 revenue estimations are presented for 2019 and forecasts for 2023 and 2028.

The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors.

The study presents detailed market analysis with inputs derived from industry professionals across the value chain. A special focus has been made on 23 countries such as U.S., Canada, Mexico, U.K., Germany, Spain, France, Italy, China, Brazil, Saudi Arabia, South Africa, etc.

The market data is gathered from extensive primary interviews and secondary research. The market size is calculated based on the revenue generated through sales from all the given segments and sub segments in the research scope. The market sizing analysis includes both top-down and bottom-up approaches for data validation and accuracy measures.

Report Highlights:

Key Topics Covered:

1 Market Outline

1.1 Research Methodology

1.1.1 Research Approach & Sources

1.2 Market Trends

1.3 Regulatory Factors

1.4 Application Analysis

1.5 Strategic Benchmarking

1.6 Opportunity Analysis

2 Executive Summary

3 Market Overview

3.1 Current Trends

3.1.1 Rise in Focus on Preventive Healthcare

3.1.2 Growing Application Profiling and Existing Applications

3.1.3 Increase in Demand for Food Fortification

3.1.4 Growth Opportunities/Investment Opportunities

3.2 Drivers

3.3 Constraints

3.4 Industry Attractiveness

3.4.1 Bargaining power of suppliers

3.4.2 Bargaining power of buyers

3.4.3 Threat of substitutes

3.4.4 Threat of new entrants

3.4.5 Competitive rivalry

4 Omega-3 Market, By Type

4.1 Eicosapentaenoic Acid (EPA)

4.2 Docosahexaenoic Acid (DHA)

4.3 Alpha-Linolenic Acid (ALA)

5 Omega-3 Market, By Distribution Channel

5.1 Pharmacies and Drug Stores

5.2 Internet Retailing

5.3 Grocery Retailers

5.4 Other Distribution Channels

6 Omega-3 Market, By Source

6.1 Nuts and Seeds

6.1.1 Pumpkin Seeds

6.1.2 Walnut

6.1.3 Other Seeds

6.1.3.1 Tahini

6.1.3.2 Hazelnuts

6.1.3.3 Chia Seeds

6.2 Vegetable oils

6.2.1 Canola Oil

6.2.2 Soybean Oil

6.2.3 Other Vegetable oils

6.2.3.1 Flaxseed Oil

6.2.3.2 Olive Oil

6.3 Plant Source

6.4 Soya and Soya Products

6.4.1 Bean curd

6.4.2 Soya milk

6.5 Marine Source

6.5.1 Algal Oil

6.5.2 Fish Oil & Krill Oil

7 Omega-3 Market, By Application

7.1 Sports Nutrition

7.2 Pharmaceuticals

7.3 Pet Food and Feed

7.4 Infant Formula

7.5 Functional Foods & Beverages

7.6 Fish Feed

7.7 Dietary Supplements

8 Omega-3 Market, By Geography

8.1 North America

8.2 Europe

8.3 Asia Pacific

8.4 Middle East

8.5 Latin America

8.6 Rest of the World (RoW)

9 Key Player Activities

9.1 Acquisitions & Mergers

9.2 Agreements, Partnerships, Collaborations and Joint Ventures

9.3 Product Launch & Expansions

9.4 Other Activities

10 Leading Companies

10.1 Sinomega Biotech Engineering

10.2 Polaris

10.3 Pharma Marine

10.4 Orkla Health

10.5 Nordic Naturals

10.6 Lonza

10.7 Kinomega Biopharm

10.8 KD Pharma

10.9 Huatai Biopharm

10.10 Guangdong Runke Bioengineering

10.11 Golden Omega

10.12 GC Rieber

10.13 EPAx

10.14 DSM

10.15 Croda International

10.16 Corbion

10.17 Cargill

10.18 Biosearch Life

Read more:
2020 Report on the Global Omega-3 Market Including Analysis, Trends & Industry Forecast - Leading Companies Include Polaris, Pharma Marine &...

Maybe were all just batteries. Thats the bad news for Keanu Reeves Neo, who wakes up from a chemically-induced slumber and discovers hes nothing more than a pack of double-As connected to a massive power station run by evil robot overlords in the dystopian sci-fi film The Matrix.

But what if the power potential of human electric current wasnt so post-apocalyptic? As the International Energy Agency notes, global demand for power rose 2.3% in 2018, which represents the biggest increase in the last decade. Ever since Ben Franklin first decided that flying kites in dangerous weather was solid scientific practice, humans have been finding new ways to use electricity and discovering that demand never stops.

The bad news? Youre no coppertop. The better news? Bioelectricity is essential to life and may drive the future of human development.

Harvesting electricity from human activity is nothing new. As Knowable Magazine notes, breathing can produce more than 0.80 watts, body heat can generate up to 4.8 watts, and the motion of your arms creates a stunning 60 watts of power.

But the notion of electricity as fundamental to biological life isnt quite so clear-cut. According to Quartz, while there were some experiments measuring human electrical currents in the mid-1920s, its wasnt until 1949 that Alan Hodgkin and Andrew Huxley identified the movement of ions across cell nerve membranes. The pair took home a Nobel Prize for their work, but this electric revolution was quickly outpaced by the double-helix discovery of DNA. For decades, genes became the best-fit scientific foundation for biology, while electricity research was short-circuited.

Then, in 1976, Erwin Neher and Bert Sakmann developed a tool capable of circumventing bioelectricitys biggest problem: studying ion movements without killing their cellular transport mediums. And later, in 2012, Richard Nuccitelli created a device sensitive and subtle enough to track human electric currents on skin, and discovered that, when skin cells are wounded, they emit an injury current that calls for help from other cells. The larger the wound, the bigger the current and the current decreases with age. Other work found that charges inside embryo cells significantly affected development. As NOVA states, Researchers overwhelmingly agree that bioelectric currents are essential to nerve and muscle function.

With the human nervous system constantly generating a fluctuating electric current, why cant we all just plug in and power up? It all comes down to the two halves of electric potential: positive and negative charges.

The electricity were most familiar with the kind Franklin flew kites for and that powers our smartphones, dishwashers and light bulbs depends on the flow of negatively-charged electrons to produce a current. Meanwhile, in our bodies, its the movement of positively-charged ions such as potassium, sodium and calcium passing through cell membranes that create electric potential. And while this variable voltage is essential to keep hearts beating, limbs moving and minds functioning, its not great for typical electrical applications. For example, when animal cells take in sodium and chloride ions and discharge potassium ions, the result is a voltage between -40 to -80 mV across membranes, significantly less than a single watch battery.

However, as it turns out, human electric current offers significant potential for internal applications.

The biggest potential for human-produced power? Improved healing. Studies published in the journal Advances in Wound Care have shown that supplementing the bodys electric current with outside electrical stimulation can help to reduce the recovery time needed for bedsores, which are some of the most difficult wounds to mitigate, let alone fully heal. Similar work has shown improvements in healing bone fractures.

Next on the list? Cancer. While research in the 1920s demonstrated a connection between changing electric gradients and cancerous tumors, cell mutations are the most commonly cited cause of cancer concerns. Now, theres speculation that misregulation of electric currents may lead to cellular communication challenges in effect, cells forget theyre part of a larger network and begin acting selfishly by hoarding resources and growing out of control. Research from the University of Nottingham found that biologically-generated currents underpin specific cancer cell behaviors, and new techniques using a combination of gene therapy and light-activated ion channels have seen success treating cancer in tadpoles.

However, despite steady progress, challenges remain. Human genomes are far more complex than those of rats or tadpoles, and gene therapies face significant regulatory challenges. Electric treatments for wound healing also struggle with standardization how long should currents be applied to wounds for maximum effect without causing secondary damage? At what voltage? Using what type of device? Is alternating current (AC) or direct current (DC) safer? More effective?

The result is a kind of cautious optimism. While bioelectric benefits are grounded in solid science, more testing and research is necessary to standardize and streamline medical processes.

Bioelectric research offers the tantalizing potential to tap the inherent power of the human nervous system, but were not there yet.

Still, theres good reason to be optimistic. Mike Levin of Tufts University, whose lab is on the leading edge of human electric current research, puts it simply: Understanding the bioelectricity, biomechanics, and transcriptional circuits that allow cells to cooperate toward large-scale goals is the key to regenerative medicine, birth defects, cancer reprogramming, aging, synthetic bioengineering, and even new AI.

Put simply? Were not batteries thanks to positive bioelectric potential, were even better.

Read more here:
Batteries Included? The Power Potential of Human Electric Current Now. Powered by - Now. Powered by Northrop Grumman.

Ultrafiltration Membrane Market

The Global Ultrafiltration Membrane MarketResearch Report Forecast 2019-2025:The research study has been prepared with the use of in-depth qualitative and quantitative analyses of the global Ultrafiltration Membrane Market. The report offers complete and intelligent analysis of the competition, segmentation, dynamics, and geographical advancement of the Global Ultrafiltration Membrane Market. It takes into account the CAGR, value, volume, revenue, production, consumption, sales, Manufacturing cost, prices, and other key factors related to the global Market.

Get PDF Sample Copy of this Report:

https://www.marketinsightsreports.com/reports/03011120109/global-ultrafiltration-membrane-market-insights-forecast-to-2025/inquiry?mode=31.

Key Players of the Market:

Asahi Kasei, GE Water & Process Technologies, Evoqua, DOW, Toray, 3M (Membrana), Mitsubishi Rayon, Nitto Denko Corporation, Degremont Technologies, Basf, Synder Filtration, Microdyn-Nadir, Canpure, Pentair(X-Flow), Applied Membranes, CITIC Envirotech, Litree, Origin Water, Tianjin MOTIMO, Zhaojin Motian

Segmentation by product type:

Inorganic Membrane

Organic Membrane

Segmentation by application:

Food & Beverage

Industrial & Municipal

Healthcare & Bioengineering

Seawater Reverse Osmosis

Potable Water Treatment

Full Copy Of Report:

https://www.marketinsightsreports.com/reports/03011120109/global-ultrafiltration-membrane-market-insights-forecast-to-2025?mode=31.

Market Segment by Regions, regional analysis covers 2019-2025:

North America(United States, Canada and Mexico)Europe(Germany, France, UK, Russia and Italy)Asia-Pacific(China, Japan, Korea, India and Southeast Asia)South America(Brazil, Argentina, Colombia etc.)Middle East and Africa(Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Influence of the Ultrafiltration Membrane market report:

-Comprehensive assessment of all opportunities and risk in the Ultrafiltration Membrane market

-Ultrafiltration Membrane market recent innovations and major events

-Detailed study of business strategies for growth of the Ultrafiltration Membrane market-leading players.

-Conclusive study about the growth plot of Ultrafiltration Membrane market for forthcoming years.

-In-depth understanding of Ultrafiltration Membrane market-particular drivers, constraints and major micro markets.

-Favourable impression inside vital technological and market latest trends striking the Ultrafiltration Membrane market.

What are the Ultrafiltration Membrane market factors that are explained in the report?

-Key Strategic Developments:The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

-Key Market Features:The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

Analytical Tools:The Global Ultrafiltration Membrane Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, SWOT analysis, feasibility study, and investment return analysis have been used to analyze the growth of the key players operating in the market.

About Us:-

MarketInsightsReports provides syndicated market research reports to industries, organizations or even individuals with an aim of helping them in their decision making process. These reports include in-depth market research studies i.e. market share analysis, industry analysis, information on products, countries, market size, trends, business research details and much more. MarketInsightsReports provides Global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:

Irfan Tamboli (Head of Sales) Market Insights ReportsPhone: + 1704 266 3234 | +91-750-707-8687[emailprotected]|[emailprotected]

See the rest here:
Ultrafiltration Membrane Market 2019 Growth, Trends, and Forecast 2025 - Instant Tech News

On Valentines Day, BioSpace would be remiss not to mention, er, matters of the heart. There are reportedly 59 life sciences companies or organizations worldwide that focus on the cardiovascular system, ranging from the Aab Cardiovascular Research Institute based in West Henrietta, New York to XyloCor Therapeutics, headquartered in Philadelphia, Pennsylvania. That number is probably low.

But no matter how you look at it, there is a significant amount of work being done on cardiovascular diseases. Heres a look at just some of the recent news.

On January 28, 2020, the U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Companys Trijardy XR for lowering blood sugar in adults with type 2 diabetes.

Trijardy XR is a triple-combination pill that includes Jardiance (empagliflozin), Tradjenta (linagliptin) and metformin hydrochloride extended release. It is prescribed along with diet and exercise for decreasing blood glucose levels in type 2 diabetes.

In the U.S., Jardiance and Radjenta are once-daily tablet used to treat adults with type 2 diabetes. Jardiance has also been approved to decrease the risk of cardiovascular death in adults with type 2 diabetes with known cardiovascular disease.

On February 3, 2020, researchers with the University of South Florida (USF Health) identified key mechanisms behind the loss of capillaries, which drives numerous diseases, including high blood pressure, diabetes, malignant cancer and a variety of cardiovascular and neurodegenerative diseases.

Capillary regression (loss) is an underappreciated, yet profound, feature of many diseases, especially those affecting organs requiring a lot of oxygen to work properly, said George Davis, professor of molecular pharmacology and physiology at the USF Morsani College of Medicine in Tampa, Florida. If we know how blood vessels are altered or begin to break down, we should be able to fix it pharmacologically.

Davis led a research project that identified the three major proinflammatory mediators that drive capillary loss. They published the research in the journal Arteriosclerosis, Thrombosis, and Vascular Biology.

The mediators are interleukin-1 beta (IL-1), tumor necrosis factor alpha (TNFalpha) and thrombin). They found that individually and even more so when combined, these directly drive capillary regression. They also identified drug combinations that can neutralize antibodies that specifically block IL-1 and TNFalpha, that can interfere with this capillary loss.

On January 27, 2020, AstraZeneca announced that its Brilinta (ticagrelor) hit the primary endpoint in the Phase III THALES trial in stroke. The study showed that 90mg of Brilinta twice a day and taken with aspirin for 30 days, provided a statistically significant and clinically meaningful decrease in the risk of stroke and death compared to aspirin alone. The trial was run in more than 11,000 patients who had a minor acute ischemic stroke or high-risk transient ischemic attack (TIA) in 24 hours before the beginning of treatment.

Results of the Phase III THALES trial showed Brilinta, in combination with aspirin, improved outcomes in patients who had experienced a minor acute ischemic stroke or high-risk transient ischemic attack, said Mene Pangalos, executive vice president, BioPharmaceuticals R&D. We look forward to sharing the detailed result with health authorities.

Earlier that month, however, the company announced that after a recommendation from an independent Data Monitoring Committee, it was abandoning its Phase III STRENGTH trial for Epanova (omega-3 carboxylic acids) for mixed dyslipidemia (MDL). Epanova is a fish oil-derived combination of free fatty acids composed mostly of EPA and DHA. It was approved in the U.S. as an adjunct to diet to decrease triglyceride levels in adults with severe high triglycerides. That indication wasnt changed by the data from the STRENGTH trial.

AstraZenecas exit from the fish oil drug trial largely leaves Amarin Corporations Vascepa (icosapent ethyl) as the only fish-oil drug to not only treat high triglycerides, but to decrease the risk of first and subsequent heart attacks, strokes and heart problems. In its clinical trials, Vascepa decrease those risks by 30%.

Although derived from fish, Vascepa is not fish oil. It is made up of the omega-3 acid (EPA) in ethyl-ester form. It was designated a new chemical entity by the FDA,

The same day AstraZeneca made their announcement, another company in the market space, Acasti Pharma, also reported a failure. Its own fish oil-based candidate, CaPre (omega-3 phospholipid) for severe hypertriglyceridemia, announced topline data from its Phase III TRILOGY 1 trial. Although it reported a 30.5% median reduction in triglyceride levels compared to 27.5% in the placebo group at 12 weeks, as well as a 42.2% decrease in patients on background statins compared to 31.5%, because of an unexpectedly large placebo response, the trial did not reach statistical significance.

And as long as were belaboring the Matters of the Heart theme, in mid-December 2019, Vancouver, British Columbia-based Novoheart signed an exclusive licensing deal with Harvard Universitys Office of Technology Development.

The deal allows Novoheart to merge its MyHeart Platform with Harvards tissue-engineered scale model of the heart ventricle and bioreactor technology. Novoheart invented and commercialized the first and only human heart-in-a-jar model for drug discovery and development.

Harvards valved bioreactor technology was engineered in Kevin Kit Parkers laboratory. He is the Tarr Family Professor of Bioengineering and Applied Physics at Harvard A. Paulson School of Engineering and Applied Sciences.

The two institutions expect that the merged technology will result in a next-generation human heart-in-a-jar that will be a superior human heart model for disease modeling, drug discovery and development with unmatched biofidelity as well as significantly enhanced predictive accuracy, capacity and versatility.

In addition to developing various bioengineered human heart constructs, Novoheart wants to develop the technology into transplantable grafts for cell-based regenerative heart therapies. The companys various products include Human Ventricular Cardiomyocytes (hvCM), Cardiac Anisotropic Sheet (hvCAS), Cardiac Tissue Strip (hvCTS), and Cardiac Organoid Chamber (hvCOC). It also offers consultation and screening and phenotyping services using its 2D or 3D tissue assays.

On November 26, Novoheart announced a collaboration with AstraZeneca to develop the worlds first human-specific in vitro, functional model of heart failure with preserved ejection fraction (HFpEF). Working with AstraZenecas Cardiovascular, Renal and Metabolism team, they will initially establish a new in vitro model using Novohearts proprietary 3D human ventricular cardiac organoid chamber (hvCOC), also known as the human heart-in-a-jar.

Overall, we dont recommend buying your sweetheart a heart in a jar. Go with the classicschocolates or flowers, instead.

BioSpace source:

https://www.biospace.com/article/valentine-s-day-matters-of-the-heart-biopharma-style

See original here:
Valentine's Day Matters of the Heart, Biopharma-Style - PharmaLive

Noah Hill was turning in his physics homework as a first-year student in fall 2016 when he spied a poster advertising a three-day event for Tufts engineering startups.

I had just come to college, and entrepreneurship was all new to me, he said. He went to the event, and wound up in a group with two older students, Daniel Weinstein, E18, and Saam Borzog, D19. They were exploring a small device that would fit inside a persons mouth and track the nutritional content of what they were eating.

Over the next seventy-two hours, the three bonded over the idea so well that when the event was over, they decided to keep working on the project. I had no idea what I was getting myself into, said Hill, E21, a computer science major.

From that chance meeting grew their company UChu Biosensors, a dental technology startup that they hope will revolutionize the way dentists use real-time data to fight tooth decay. The company has shown so much promise that Hill took this year off from Tufts to travel to Shenzhen, China to work on the product at the HAX Accelerator, which provides venture capital and services to develop hardware.

My philosophy is that college will always be there, but I dont know if I can be director of software engineering of my own company, he said. Worst case scenario, this falls through and I finish my degree; best case, I keep working and can pay for my own tuition.

Hill grew up in Tacoma, Washington, where his dad worked for a nearby citys public works department. Hill tinkered with him in the garage during the weekends. He would buy old, broken cars on purpose so he could fix them, said Hill, who developed a love for math and engineering.

It wasnt until he came to Tufts that he discovered computer programming, first taking a class on it at the Experimental College. When Hill first learned how to program a Raspberry Pi, a palm-sized minicomputer, and made it print on a terminal, it blew my mind, he said. Ever since then, Ive wanted to program things.

The three-member team ran with the idea of the diet tracker for more than year before realizing that tracking so many nutrients was too complicated. Borzog, then a student at the Tufts dental school, had an aha moment, remembering how much his professors preached the importance of acidity in tooth decay.

Acid is to dental health what blood pressure it to heart disease, said Borzog. Outside of a twice-yearly checkup, however, dentists have no way to understand what is going on in peoples mouths. We usually recommend the same thing for each patientbrush and floss twice a day.

The issue is particularly important for millions of people who are more prone to dental decay, such as those on antidepressants or living with diabetes and cancer, for example. The company shifted its vision toward a device that would attach to a patients tooth and continually monitor acid levels, sending an alert to a smartphone if it rose to a critical level.

That would allow a dentist to prescribe a specific toothpaste or mouthwash to bring down acidity. Ninety-two percent of people will experience tooth decay at some point, and its completely preventable, Hill said.

Over the past two years, the team worked to create a prototype, with Weinstein overseeing the bioengineering, Borzog the dental science, and Hill the computer programming. Hills computer science courses at Tufts became real-time tutorials to create the company software.

Comp 40 skyrocketed my ability to write code, said Hill, who at one point was dealing with a software bug for two weeks. In class, they taught us how to debug assembly code, and within fifteen minutes, Id fixed it.

At the same time, the trio was buoyed by the Tufts Entrepreneurship Center, winning its $15,000 Montle Prize and $5,000 Ricci Prize in 2017. That in turn garnered the interest of thencenter director Jack Derby and other faculty members, who helped the trio hone their message and connected them with potential funders.

The science is there, but the guys also have very positive and friendly attitudes, said Derby, now a lecturer at the Tufts Gordon Institute. That makes all of us in the center want to do more for them.

Working at Tufts Launchpad | BioLabs, the team created a proof of concepta complete working sensor on a mouthguard, and with Derbys help, began traveling around the country and overseas making a pitch for funding.

The teams drive and persistence are unique among Tufts students, says computer science associate teaching professor Ming Chow, E02, EG04, who taught Hill in Web Programming in spring 2018. Tufts talks about entrepreneurship, Chow said, and now Noah has gone on to do it.

With an initial goal of raising $500,000, the company was only able to bring in $291,500 before the opportunity with HAX came along. The accelerator provides companies with $250,000 in venture capital, as well as engineering and marketing teams, to complete their product. The only catch is that they have to move to China to do it.

Hill didnt hesitate, leaving Tufts this fall to travel with Weinstein to Shenzhen, where the two have worked twelve-to-sixteen hour days to design the hardware, firmware, server architecture, and web interface.

When they are done with the product design, they will then head to Silicon Valley in the spring in hopes of raising $2 to $3 million in seed capital to see the device through the regulatory process. If all goes well, they hope to sell to their first patients in 2021 or 2022.

The experience has brought out my inner strength and helped me realize what Im passionate about, said Hill, reflecting on how far hes come since that startup event his first year at Tufts. Whatever you want to do is really possible if you work hard and meet people and leverage the resources that are available.

Michael Blanding is a Boston-based freelance writer.

Here is the original post:
Taking the Leap into the Startup Worldas a Student - Tufts Now